Now I have all the information I need. Let me produce the final consolidated review.

## Summary

The paper introduces HG-DCM (History-Guided Deep Compartmental Model), a framework that transfers knowledge from multiple historical pandemics (Ebola, SARS, Dengue, seasonal influenza) to improve early-stage ("cold-start") forecasting of a novel outbreak. The method uses a ResNet-based parameter predictor to map early time-series and metadata to DELPHI compartmental model parameters, then solves the ODE system to generate forecasts. The core idea—using biologically distinct historical outbreaks to regularize a compartmental model for a new pandemic—is well-motivated and novel.

---

## Strengths

1. **Novel cross-disease transfer framework with mechanistic grounding.** HG-DCM is among the first works to systematically integrate data from multiple biologically distinct past pandemics into a deep compartmental forecasting pipeline. The combination of a learned parameter predictor with an interpretable ODE-based epidemiological model (DELPHI) is a principled design that preserves both expressiveness and interpretability.

2. **Ablation cleanly isolates the value of historical data.** The T-DCM ablation (identical architecture, trained without historical pandemic data) is the right control. Table 2 shows HG-DCM consistently beats T-DCM on median MAE across all training window lengths, demonstrating that adding historical outbreak data improves forecasts on the target disease.

3. **Practical improvement in forecast stability.** Figure 4a quantifies overshoot events (predicted cumulative cases >5× observed): HG-DCM produces substantially fewer catastrophic failures than DELPHI across all training lengths. This is a practically meaningful benefit for public health decision-making.

4. **More stable and plausible parameter estimates.** Section 3.2.3 (Figure 5) shows HG-DCM produces tighter interquartile ranges for DELPHI parameters than fitting DELPHI independently per location, with statistically significant differences (Wilcoxon, p<0.05). This confirms that historical data regularizes parameter inference.

5. **Architectural adaptation for cross-disease distribution shift.** The removal of Batch Normalization from the ResNet backbone (Section 2.1) is a targeted, problem-specific modification justified by the observation that batch statistics differ across historically distinct pandemics.

6. **New pandemic dataset compiled.** The authors constructed and publicly document a dataset spanning multiple global outbreaks with associated metadata, which is a useful contribution to the community.

---

## Weaknesses

### Fatal
None.

### Major

1. **Selective reporting of results masks a significant mean–median discrepancy.** At 4 weeks, HG-DCM's mean MAE (110,452.4) is ~62× its median (1,770.9), while CNN's mean MAE at 4 weeks (11,238.1) is an order of magnitude lower than HG-DCM's. The paper claims "CNN generally underperforms HG-DCM across all training horizons" — but for mean MAE, CNN is better at both 2 weeks (15,600.4 vs 18,602.6) and 4 weeks (11,238.1 vs 110,452.4). The paper never mentions or explains this mean spike, and relies entirely on median MAE to support its claims without justifying the choice or discussing the outliers that drive the mean apart. This undermines trust in the reported results.

2. **Overclaim at 8-week training horizon.** The paper states HG-DCM "consistently outperforms DELPHI across forecasting horizons," but at 8 weeks DELPHI achieves lower median MAE (537.7 vs 796.0). The 6- and 8-week results are at best comparable, and the blanket claim of consistent outperformance is not supported by the data.

3. **No held-out pandemic evaluation.** The central advertised contribution is forecasting a *novel* pathogen by transferring knowledge from past pandemics. However, the model is only evaluated on COVID-19, which is included in the training set (even if only early data). The strongest evidence for cross-disease generalization would be a held-out pandemic — e.g., training on all past pandemics plus COVID-19, then testing on SARS, or leaving out one historical pandemic entirely and using it as a zero-shot target. The current design (with T-DCM ablation) does provide some evidence for cross-disease transfer, but the paper would be substantially stronger with a held-out evaluation.

4. **External baseline comparison is severely limited.** The comparison against GradABM and EiNNs is restricted to only two locations (US and Massachusetts). The paper acknowledges this limitation but does not explore what can be done to broaden it. The main ablation baselines (DELPHI, CNN, T-DCM) are reasonable, but the absence of any simple non-deep-learning baselines (e.g., SEIR with curve fitting, exponential growth models) makes it hard to contextualize the reported gains.

### Minor

5. **Loss hyperparameters α and β are not analyzed.** The objective function (Eqns. 3–5) depends on α (balancing MAE and MAPE) and β (balancing past and current pandemic losses). No sensitivity analysis or ablation is provided, so it is unclear how sensitive results are to these choices.

6. **No uncertainty quantification.** The paper produces only point forecasts of cumulative cases, without prediction intervals. For a tool intended to inform public health decisions, this is a significant practical limitation. (Noted as future work, but could be addressed more directly.)

7. **The parameter inference analysis (Section 3.2.3) is qualitative and not validated against ground truth.** The box plots show HG-DCM produces tighter parameter distributions than DELPHI, but there is no evidence that these parameters are *correct* — only that they are more constrained. The paper does not connect the parameter analysis to any ground-truth parameter validation.

### Trivial
None.

---

## Nice-to-Haves
- Release of the compiled pandemic dataset and code would strengthen reproducibility and community impact.
- Sensitivity analysis for the BN removal decision: the paper states BN was removed for principled reasons but provides no experiment validating this choice.
- Including CNN in the overshoot analysis (Figure 4a caption mentions it does include CNN).

---

## Removed Points
These points are flagged to be removed; treat them with caution:
- "Figure 3 x-axis scale not visible" — The parser strips images; the reviewer cannot confirm this claim from the text alone.
- "The paper does not report overshooting for the CNN baseline" — Factually incorrect; Figure 4a caption explicitly includes CNN.
- "No code or data release is mentioned" — The paper is under double-blind review; release is typically deferred.
- Missing related work / literature gaps — The paper cites relevant work; I cannot independently verify what is missing.
- Formatting/style nitpicks and claims about missing appendix sections — Parser artifacts, not author errors.

---

## Novel Insights

None beyond the paper's own contributions. The reviews surface a genuine tension: the paper's core methodological contribution (cross-disease temporal transfer for compartmental models) is well-motivated and architecturally sound, but the experimental evaluation has a selective-reporting problem that undermines confidence in the headline claims. A held-out pandemic evaluation would be the cleanest way to resolve this tension, but even without it, the paper would benefit from honestly addressing the mean–median gap and toning down the overclaims.

---

## Suggestions
1. **Address the mean MAE spike.** Explain why HG-DCM's mean jumps to 110,452 at 4 weeks but its median is only 1,770. Report the number and nature of outlier predictions (e.g., which locations, what case magnitudes). If the metric of choice is median, justify this explicitly and acknowledge the mean behavior.
2. **Add a held-out pandemic evaluation.** Even a single held-out target (e.g., training on all diseases including COVID-19 and testing on SARS, or a leave-one-pandemic-out cross-validation) would substantially strengthen the cross-disease generalization claim.
3. **Tone down overclaims.** Replace "consistently outperforms DELPHI across forecasting horizons" with a more nuanced statement that acknowledges the 8-week median results and specifies the regimes where HG-DCM provides clear benefit (2–4 weeks, overshoot reduction).
4. **Provide hyperparameter sensitivity analysis** for α and β.
5. **Add simple baselines** such as exponential growth models or SEIR+curve-fitting to contextualize the magnitude of gains from the deep learning approach.

---

## Score and Decision

**Calibration Anchors (all rounds)**

*Round 1 (bracketing):*
- `/home/wg25r/review_agent/human_reviews/CpiOUOaqh3.md` — avg 2.00: A parameter optimization study for an SEIR variant applied locally in Brazil. Narrow scope, limited evaluation, much weaker methodologically and in ambition than HG-DCM.
- `/home/wg25r/review_agent/human_reviews/fzZfju8y0g.md` — avg 3.40: In-context learning for neural PDE solvers. Topically adjacent (ODE-based forecasting) but does not address the cross-disease transfer problem. Comparatively weaker empirical evaluation.
- `/home/wg25r/review_agent/human_reviews/DL7JWbdGr3.md` — avg 4.75: PEMs pre-trains epidemic time-series models on multiple diseases and tests on novel COVID-19. Most topically similar to HG-DCM. Strengths: held-out COVID-19 evaluation; weaknesses: no mechanistic grounding, limited baselines, no Forecast Hub comparison. HG-DCM has stronger methodological novelty (compartmental + DL) but weaker evidence (no held-out pandemic, reporting issues). Comparable overall quality.
- `/home/wg25r/review_agent/human_reviews/gQlxd3Mtru.md` — avg 8.67: Learning stochastic dynamics via optimal transport. Rigorous theory, strong experiments, top venue. Substantially stronger than HG-DCM in all dimensions.

*Round 2 (narrowing within 4–6 bracket):*
- `/home/wg25r/review_agent/human_reviews/DL7JWbdGr3.md` — avg 4.75 (re-read): See above.
- `/home/wg25r/review_agent/human_reviews/i1BTP8wFYM.md` — avg 5.25: Pre-trained dynamics encoder (PDEDER) for cross-domain dynamics. Similar in approach (pre-train on multiple systems, fine-tune) but applied to general dynamical systems. Stronger cross-domain evaluation; weaker problem motivation. HG-DCM has a more compelling applied problem but not enough to score higher given its reporting gaps.
- `/home/wg25r/review_agent/human_reviews/7xJgPtLHfm.md` — avg 5.00: cd-PINN for continuous dependence in PINN. Cleaner theoretical framing but simple experiments. Comparable overall quality to HG-DCM but for different reasons.
- `/home/wg25r/review_agent/human_reviews/TwMLUpPg8G.md` — avg 5.00: Physics law discovery via invariant function learning. Theory-driven, limited empirical scope. Comparable to HG-DCM in overall quality.
- `/home/wg25r/review_agent/human_reviews/BuFNoKBiMs.md` — avg 6.33: Decoupled MTPP with Neural ODEs. Accepted as poster. Stronger evaluation and clearer claims than HG-DCM.

**Round 1 bracket:** 4–6.

**Narrowing:** HG-DCM is most comparable to PEMs (avg 4.75). Both address cross-disease epidemic forecasting. PEMs has stronger held-out evaluation but weaker methodology (pure transformer vs. compartmental+DL). HG-DCM has a more novel architecture but an unaddressed mean/median discrepancy and overclaimed results that PEMs does not exhibit. On balance, HG-DCM is slightly below PEMs in overall convincingness, placing it near the lower end of the bracket. Score anchored at 5.0 — the paper makes a genuine contribution but the evaluation weaknesses (selective reporting, overclaim, limited external baselines) are serious enough that the central claims are not yet fully supported.

MY FINAL SCORE: 5.0
MY FINAL DECISION: Reject